Helen Hobbs - Pfizer Independent Director

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>PFE</div>
PFE -- USA Stock  


Dr. Helen H. Hobbs, M.D., is an Independent Director of Pfizer Inc., since December 12, 2011. She is Investigator, the Howard Hughes Medical Institute since 2002, Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. Received both the Clinical Research Prize and Distinguished Scientist Award from the American Heart Association. In 2012, received the inaugural International Society of Atherosclerosis Prize and in 2015, received both the Pearl Meister Greengard Award and the Breakthrough Prize in Life Sciences. In 2016, received the Passano Award and the Gill Award
Age: 66  Director Since 2011      
212 733-2323  www.pfizer.com
Hobbs? background reflects significant achievements in academia and medicine. She has served as a faculty member at the University of Texas Southwestern Medical Center for more than 20 years and is a leading geneticist in metabolism and heart disease, areas in which Pfizer has significant investments and experience. Pfizer benefits from her experience, expertise, achievements and recognition in both medicine and science.

Management Efficiency

The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


Gayle WilsonGilead Sciences
Harish ManwaniGilead Sciences
John CoganGilead Sciences
Kelly KramerGilead Sciences
Michael GrobsteinBristol Myers Squibb Company
Christopher CoughlinAllergan Plc
Weiying WangAstrazeneca PLC
Nancy AndrewsNovartis AG
Ton BuechnerNovartis AG
Daniel PodolskyGlaxoSmithKline PLC
Carol DavidsonAllergan Plc
Pamela CraigMerck Company
Carla HillsGilead Sciences
Peter McDonnellAllergan Plc
Stacey CartwrightGlaxoSmithKline PLC
David HooverEli Lilly And Company
Carlos RepresasMerck Company
Baroness VaderaAstrazeneca PLC
Ralph AlvarezEli Lilly And Company
Peter ArduiniBristol Myers Squibb Company
John NoseworthyMerck Company

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer (PFE) is traded on BATS Exchange in USA. It is located in 235 East 42nd Street, New York, NY 10017, United States and employs 88,300 people. Pfizer is listed under Pharmaceutical Products category by Fama And French industry classification.

Pfizer Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela HwangView
Jennifer Damico, Senior Vice President Principal Accounting Officer, ControllerView
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global SupplyView
Douglas Lankler, Executive Vice President General CounselView
Dawn Rogers, Chief Human Resource Officer, Executive Vice PresidentView
Helen Hobbs, Independent DirectorView
Shantanu Narayen, Lead Independent DirectorView
James Smith, Independent DirectorView
Dennis Ausiello, Independent DirectorView
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and MedicalView
Frances Fergusson, Independent DirectorView
Stephen Sanger, Independent DirectorView
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital OfficerView
Gordon Loh, Senior Vice President Corporate AuditView
Wyllie Cornwell, Independent DirectorView
Suzanne Johnson, Independent DirectorView
Alexander Mackenzie, Executive Vice President Chief Development OfficerView
Geno Germano, Group President of Global Innovative Pharma Bus.View
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial OperationsView
Sally Susman, Chief Corporate Affairs Officer, Executive Vice PresidentView
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global SupplyView
Susan Hockfield, Independent DirectorView
Freda LewisHall, Executive Vice President Chief Medical OfficerView
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice PresidentView
Dan Littman, Independent DirectorView
Ian Read, Chairman, CEO and Chairman of Executive CommitteeView
James Kilts, Independent DirectorView
Don Cornwell, Independent DirectorView
James Quincey, Independent DirectorView
Charles Hill, Executive Vice President - Worldwide Human ResourcesView
Joseph Echevarria, Independent DirectorView
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare BusinessView
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global SupplyView
Angela Hwang, Group President, Pfizer Biopharmaceuticals GroupView
Scott Gottlieb, Independent DirectorView
Ronald Blaylock, Independent DirectorView
Kathrin Jansen, Senior Vice President - Vaccine Research & DevelopmentView
Michael Goettler, Group President - Pfizer UpjohnView

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now


Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 100 shares of
3 days ago
Traded for 2.34
Purchased over 70 shares of
3 days ago
Traded for 42.57
Purchased over 100 shares of
3 days ago
Traded for 25.97
Purchased few shares of
3 days ago
Traded for 161.56
Purchased over 20 shares of
3 days ago
Traded for 115.74
Please check Your Equity Center. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page